According to the aim of this study, we first analyzed CD44 expression in a cohort of human patients with cirrhosis (n = 10) and in HCC patients of mixed etiology (n = 67), including HCC related to metabolic syndrome diseases (NAFLD/NASH). The gene discussed is CD44; the disease is hepatocellular carcinoma.